𝔖 Bobbio Scriptorium
✦   LIBER   ✦

49LBA Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC)

✍ Scribed by P. Mulders; R. Hawkins; P. Nathan; I. de Jong; S. Osanto; E. Porfiri; A. Protheroe; B. Mookerjee; L. Pike; M.E. Gore

Book ID
119600826
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
47 KB
Volume
7
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; Frédéric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 3 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p

Gemcitabine and oxaliplatin in the treat
Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma : Final results of a single-institution Phase II study
✍ Camillo Porta; Matteo Zimatore; Ilaria Imarisio; Anna Natalizi; Andrea Sartore-B 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB 👁 3 views

## Abstract ## BACKGROUND Currently, there is no standard treatment for patients with advanced renal cell carcinoma (RCC) who do not experience a response to first‐line immunotherapy. In the current Phase II study, the authors explored the antitumor activity of a combination of gemcitabine and oxa